Lonza Completes Expansion of Conjugation Facility in Visp (CH)

• Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates
• The Visp (CH) investment includes two manufacturing suites and supporting infrastructure
• Additional manufacturing suites complement recent investments in Visp (CH) across small molecules and biologics development and manufacturing, including drug product

Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, announced today that a planned expansion of its bioconjugation facility in Visp (CH) is complete. 

The expansion includes two manufacturing suites and supporting infrastructure. It will support an extended customer portfolio, including companies entering clinical development. The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates. 

The new suites complement Lonza’s recent investments and asset extensions in Visp (CH) in mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity. These continued investments into the Visp (CH) site provide a flexible solution for customers of all sizes at a single location. They are designed to help customers navigate the risks of a complex bioconjugation supply chain. In addition to the two new manufacturing suites, the expansion also includes an increase in process and analytical development and quality control capacity to support future portfolio growth.

Stefan Egli, Vice President, Head of Bioconjugates, Lonza, commented: “The opening of the new bioconjugate manufacturing suites in Visp (CH) reflects our dedication to continuously improving our offering and expertise in line with anticipated market and customer needs. Combined with our offerings across drug substance and drug product manufacturing in small molecules and biologics, our bioconjugation services can support projects from early phase through to late-stage and commercial programs.”

As the leading CDMO for bioconjugates, Lonza offers customers a fully integrated solution, including the different technologies required to deliver safe and reliable bioconjugate products. 

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.